GAC ... the short term financing situation, and regulatory are my two primary items. The Hepa info re renal P3 adds an interesting piece.

But, I am just not very optimistic about the market and pps for RVX as a standalone stock unless/until there is significant news about partnering for the long haul, either a joint partnership with a road map to commercialization (or a buy out). And I think that is dependent on regulatory news (for partnering/valuation) to paint the fuller picture for a partner/buyer. Short term financing (12 months or less) is more for operational, regulatory, and negotiating breathing room toward the real goals. 

Just don't see a reason to believe that RVX will be going it alone for very long, unless BT status is achieved to an extent of HIGH promise, and indicates a shorter and clearer path to approval, that more money can get behind for a while longer? ... but, still motivated toward the real goal of buy out, but at a MUCH higher valuation as we get closer to approval opportunities and further de-risked.  

JMHO